Aquestive Therapeutics, Inc. (AQST) Q2 FY26 Earnings Call

ANAFILM resubmission is on track, but FDA timing and approval remain the key value-driving uncertainties [3][12].

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-11
Length61 minutes
EPS$-0.18
EPS consensus$-0.10
Revenue$13.8M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All AQST earnings ยท Back to AQST overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.